Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors
1999
Effects of Bryostatin-1 on Chronic Myeloid Leukaemia
Sample size: 23
publication
Evidence: moderate
Author Information
Author(s): Thijsen S F T, Schuurhuis G J, Oostveen J W van, Theijsmeijer A P, van der Hem K G, Odding J H, Dräger A M, Ossenkoppele G J
Primary Institution: Free University Hospital
Hypothesis
Does bryostatin-1 treatment affect colony-forming unit–granulocyte macrophage capacity in chronic myeloid leukaemia patients?
Conclusion
Bryostatin-1 selectively inhibits chronic myeloid leukaemia growth at the LTCIC level.
Supporting Evidence
- Bryostatin-1 induces macrophage differentiation and suppresses colony growth in vitro.
- At the CFU–GM level, bryostatin-1 treatment resulted in a 1.4-fold higher reduction of CML colony growth.
- At the LTCIC level, a sixfold higher reduction of CML growth was observed.
Takeaway
Bryostatin-1 can help stop the growth of certain cancer cells in the blood by making the good cells stronger.
Methodology
The study involved treating cells from CML patients and controls with bryostatin-1 and analyzing colony growth and stem cell frequency.
Participant Demographics
14 chronic myeloid leukaemia patients and 9 controls.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website